Systemic lipopolysaccharide (LPS) administration induces an innate immune response and stimulates the hypothalamic-pituitary-adrenal axis. We studied Angiotensin II AT 1 receptor participation in the LPS effects with focus on the pituitary gland. LPS (50 lg/kg, i.p.) enhanced, 3 h after administration, gene expression of pituitary CD14 and that of Angiotensin II AT 1A receptors in pituitary and hypothalamic paraventricular nucleus (PVN); stimulated ACTH and corticosterone release; decreased pituitary CRF 1 receptor mRNA and increased all plasma and pituitary pro-inflammatory factors studied.
Renin-angiotensin system Inflammation IL-6 LIF NF-jB COX-2 iNOS NOS activity HPA axis Paraventricular nucleus a b s t r a c t Systemic lipopolysaccharide (LPS) administration induces an innate immune response and stimulates the hypothalamic-pituitary-adrenal axis. We studied Angiotensin II AT 1 receptor participation in the LPS effects with focus on the pituitary gland. LPS (50 lg/kg, i.p.) enhanced, 3 h after administration, gene expression of pituitary CD14 and that of Angiotensin II AT 1A receptors in pituitary and hypothalamic paraventricular nucleus (PVN); stimulated ACTH and corticosterone release; decreased pituitary CRF 1 receptor mRNA and increased all plasma and pituitary pro-inflammatory factors studied.
The AT 1 receptor blocker (ARB) candesartan (1 mg/kg/day, s.c. daily for 3 days before LPS) blocked pituitary and PVN AT 1 receptors, inhibited LPS-induced ACTH but not corticosterone secretion and decreased LPS-induced release of TNF-a, IL-1b and IL-6 to the circulation. The ARB reduced LPS-induced pituitary gene expression of IL-6, LIF, iNOS, COX-2 and IjB-a; and prevented LPS-induced increase of nNOS/eNOS activity. The ARB did not affect LPS-induced TNF-a and IL-1b gene expression, IL-6 or IL-1b protein content or LPS-induced decrease of CRF 1 receptors. When administered alone, the ARB increased basal plasma corticosterone levels and basal PGE 2 mRNA in pituitary.
Our results demonstrate that the pituitary gland is a target for systemically administered LPS. AT 1 receptor activity is necessary for the complete pituitary response to LPS and is limited to specific proinflammatory pathways. There is a complementary and complex influence of the PVN and circulating cytokines on the initial pituitary response to LPS. Our findings support the proposal that ARBs may be considered for the treatment of inflammatory conditions.
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Introduction
The response to infection is a combination of immune, hormonal and behavioral adaptive responses; these include increased production of pro-inflammatory cytokines, with effects in the periphery and the brain, hypothalamic-pituitary-adrenal (HPA) axis stimulation and sickness behavior (Dantzer and Kelley, 2007; Dantzer et al., 2008) . The balance between both systems helps to fight the infection and restore homeostasis (Beishuizen and Thijs, 2004; Han and Ulevitch, 2005; Hopkins, 2007) . However, when they become unrestricted or maladaptive, homeostasis is not achieved and pathological conditions arise (Lawrence and Gilroy, 2007) . A useful experimental model and an excellent example of the immune-endocrine relationship is the systemic administration of the bacterial endotoxin lipopolysaccharide (LPS). LPS induces an innate immune response with a major upregulation of pro-inflammatory factors including enhanced pro-inflammatory cytokine production (Han and Ulevitch, 2005; Rivest, 2003) . This is accompanied by a classical stress response characterized by activation of the HPA axis (Beishuizen and Thijs, 2004; Hopkins, 2007) . During HPA axis activation, there is enhanced synthesis and release of hypothalamic corticotrophin-releasing factor (CRF) followed by an increase in pituitary ACTH formation and release, leading to augmented adrenal pro-inflammatory mineralocorticoid and anti-inflammatory glucocorticoid secretion (Elenkov and Chrousos, 2006; Fernandes et al., 2008; Grinevich et al., 2001; Moncek et al., 2003) .
The pituitary gland is a critical component for the immuneendocrine response to infection, and is a target organ for LPS (Denef, 2008; Lohrer et al., 2000; Quan et al., 1998; Ray and Melmed, 1997; Tierney et al., 2005; Wang et al., 1996; Whiteside et al., 1999; Wong et al., 1996) . The pituitary ACTH release in response to infection and stress is regulated at three levels: (a) by integrated inputs from the central nervous system, including a major role of hypothalamic CRF; (b) by an intra-pituitary network of cytokines, prostaglandins and nitric oxide; and (c) by influences from peripheral target tissues such as adrenal glucocorticoid feedback (Denef, 2008; Ray and Melmed, 1997) .
The complex paracrine network of pituitary cells is of special interest for the present study. Endotoxin injection increases the
